Elevated levels of low-density lipoprotein cholesterol (LDL-C) continue to be a major contributor to the development of atherosclerotic cardiovascular disease (ASCVD). While gold standard treatments such as statins and ezetimibe are widely available, a significant proportion of patients still do not achieve recommended LDL-C goals. Bempedoic acid, a novel oral lipid-lowering therapy, has been introduced as a third-line option with proven efficacy in clinical trials. Although clinical trials have established the efficacy of bempedoic acid, real-world evidence is essential to validate its performance in everyday clinical settings. This study investigated the impact of bempedoic acid on LDL-C reduction in patients in Germany, drawing on data from a nationally representative healthcare data base.
The study analysed 642 patients with high cardiovascular risk factors, including hypertension, diabetes, and prior heart disease. Among those not modifying other cholesterol-lowering treatments, bempedoic acid achieved an average LDL-C reduction of over 22%, with some patients experiencing reductions exceeding 60%. These results align closely with prior clinical trial data, confirming the therapy’s robust efficacy in real-world clinical settings across diverse patient populations.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Notably, bempedoic acid provided additive LDL-C-lowering benefits for patients already on other lipid-lowering therapies, reinforcing its role as a valuable third-line treatment option. However, the study also revealed that many patients still fell short of guideline-recommended LDL-C targets, underscoring the need for enhanced lipid management strategies such as combination therapies.
These real-world results align with previous clinical trial outcomes, confirming that bempedoic acid delivers substantial LDL-C reduction across diverse patient groups. Notably, its LDL-C-lowering effect persists in those already receiving other lipid-lowering treatments, highlighting the additive benefit of bempedoic acid. However, despite these encouraging effects, many patients still do not meet guideline-recommended LDL-C targets, underscoring the ongoing need for additional optimisation of lipid management such as combination therapy approaches.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
